GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

Human Reproduction Update

Volumn 22, Issue 3, 2016, Pages 358-381

  Maggi, Roberto ^a   Cariboni, Anna Maria ^a   Marelli, Marina Montagnani ^a   Moretti, Roberta Manuela ^a   Andrè, Valentina ^a   Marzagalli, Monica ^a   Limonta, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ANTAG; Endocrinology; Female infertility; GnRH AG; Gonadotrophin; Menstrual cycle

Indexed keywords

ABARELIX; ANASTROZOLE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CASPASE 3; CASPASE 7; CASPASE 8; CETRORELIX; DEGARELIX; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GOSERELIN; KISSPEPTIN; LETROZOLE; LEUPRORELIN; NEUROKININ B; PROGESTERONE; PROGESTERONE RECEPTOR; SEMAPHORIN 3A; SUBSTANCE P; TRIPTORELIN; UNINDEXED DRUG; GNRHR PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER INCIDENCE; CELL MATURATION; CELL POPULATION; DELAYED PUBERTY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE GENITAL SYSTEM; FERTILITY PRESERVATION; GONADOTROPIN SECRETING CELL; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HORMONE SYNTHESIS; HOT FLUSH; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INTRACYTOPLASMIC SPERM INJECTION; NIDATION; NONHUMAN; OSTEOPOROSIS; OVARY CARCINOMA; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RIBOSOMAL FRAMESHIFTING; TREATMENT DURATION; TROPHOBLAST; VAGINAL DRYNESS; FEMALE; GONAD; HYPOGONADISM; HYPOTHALAMUS; METABOLISM; NERVE CELL; OVARY DISEASE; PHYSIOLOGY; REPRODUCTION;

FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADS; HUMANS; HYPOGONADISM; HYPOTHALAMUS; NEURONS; OVARIAN DISEASES; RECEPTORS, LHRH; REPRODUCTION;

EID: 84965079953     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmv059     Document Type: Article

References (299)

1. Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther 2003;25:2121-2137.
2. Aboulghar MA, Marie H, Amin YM, Aboulghar MM, Nasr A, Serour GI, Mansour RT. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study. Reprod Biomed Online 2015;30:52-56.
3. Advis JP, Klein J, Kuljis RO, Sarkar DK, McDonald JM, Conover CA. Regulation of gonadotropin releasing hormone release by neuropeptide Y at the median eminence during the preovulatory period in ewes. Neuroendocrinology 2003; 77:246-257.
4. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 2011;102:51-56.
5. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; CD001750.
6. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;CD001750.
7. Baba Y, Matsuo H, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem Biophys Res Commun 1971;44:459-463.
8. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 1989;86:6318-6322.
9. Bauer-Dantoin AC, Jameson JL. Gonadotropin-releasing hormone receptor messenger ribonucleic acid expression in the ovary during the rat estrous cycle. Endocrinology 1995;136:4432-4438.
10. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978;202:631-633.
11. Betz SF, Zhu YF, Chen C, Struthers RS. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem 2008;51:3331-3348.
12. Bilotas M, Baranao RI, Buquet R, Sueldo C, Tesone M, Meresman G. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod 2007;22:644-653.
13. Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, Salvatore S, Candiani M, Venturini PL, Ferrero S. Dienogest in the treatment of endometriosis. Expert Opin Pharmacother 2014;15:1889-1902.
14. Blacker CM. Ovulation stimulation and induction. Endocrinol Metab Clin North Am 1992; 21:57-84.
15. Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better? Fertil Steril 2001;76:443-444.
16. Blumenfeld Z, Evron A. Preserving fertility whenchoosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother 2015; 16:1009-1020.
17. Blumenfeld Z, Katz G, Evron A. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation. Ann Oncol 2014; 25:1719-1728.
18. Bonomi M, Libri DV, Guizzardi F, Guarducci E, Maiolo E, Pignatti E, Asci R, Persani L. New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian J Androl 2012;14:49-56.
19. Borsay B, Skrapits K, Herczeg L, Ciofi P, Bloom SR, Ghatei MA, Dhillo WS, Liposits Z, Hrabovszky E. Hypophysiotropic gonadotropin-releasing hormone projections are exposed to dense plexuses of kisspeptin, neurokinin B and substance p immunoreactive fibers in the human: a study on tissues from postmenopausal women. Neuroendocrinology 2014;100:141-152.
20. Bouvattier C, Maione L, Bouligand J, Dodé C, Guiochon-Mantel A, Young J. Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nat Rev Endocrinol 2012;8:172-182.
21. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2014;3:CD009590.
22. Brown J, Farquhar C. An overview of treatments for endometriosis. JAMA 2015; 313:296-297.
23. Bry-Gauillard H, Trabado S, Bouligand J, Sarfati J, Francou B, Salenave S, Chanson P, Brailly-Tabard S, Guiochon-Mantel A, Young J. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. Ann Endocrinol (Paris) 2010;71:158-162.
24. Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998; 139:298-303.
25. Buck Louis GM, Peterson CM, Chen Z, Croughan M, Sundaram R, Stanford J, Varner MW, Kennedy A, Giudice L, Fujimoto VY et al. Bisphenol A and phthalates and endometriosis: the Endometriosis: Natural History, Diagnosis and Outcomes Study. Fertil Steril 2013;100:162-169 e161-162.
26. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002;955:75-85; discussion 86-78, 396-406.
27. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014;134:385-392.
28. Cardozo ER, Thomson AP, Karmon AE, Dickinson KA, Wright DL, Sabatini ME. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet 2015;32:587-596.
29. Carel JC, LEger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358:2366-2377.
30. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752-e762.
31. Cariboni A, Maggi R. Kallmann's syndrome, a neuronal migration defect. Cell Mol Life Sci 2006;63:2512-2526.
32. Cariboni A, Maggi R, Parnavelas J. From nose to fertility: the long migratory journey of gonadotropin-releasing hormone neurons. Trends Neurosci 2007;30:638-644.
33. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas J, Ruhrberg C. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism. Hum Mol Genet 2011;20:336-344.
34. Cariboni A, Andre V, Chauvet S, Cassatella D, Davidson K, Caramello A, Fantin A, Bouloux P, Mann F, Ruhrberg C. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. J Clin Invest 2015;125:2413-2428.
35. Carr BR, Marshburn PB,Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-1223.
36. Casan EM, Raga F, Bonilla-Musoles F, Polan ML. Human oviductal gonadotropinreleasing hormone: possible implications in fertilization, early embryonic development, and implantation. J Clin Endocrinol Metab 2000;85:1377-1381.
37. Casper RF. Introduction: Gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization. Fertil Steril 2015;103:865-866.
38. Celik O, Aydin S, Celik N, Yilmaz M. Peptides: Basic determinants of reproductive functions. Peptides 2015;72:34-43.
39. Chatzaki E, Bax CMR, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 1996; 56:2059-2065.
40. Chawla MK, Gutierrez GM, Young WS, McMullen NT, Rance NE. Localization of neurons expressing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol 1997;384:429-442.
41. Chen A, Yahalom D, Ben-Aroya N, Kaganovsky E,Okon E, Koch Y.Asecond isoform of gonadotropin-releasing hormone is present in the brain of human and rodents. FEBS Lett 1998;435:199-203.
42. Chen CL, Cheung LW, Lau MT, Choi JH, Auersperg N,Wang HS,Wong AS, Leung PC. Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine 2007;31:311-320.
43. Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283-306.
44. Cheng KW, Nathwani PS, Leung PC. Regulation of human gonadotropin-releasing hormone receptor gene expression in placental cells. Endocrinology 2000; 141:2340-2349.
45. Cheng G, Coolen LM, Padmanabhan V, Goodman RL, Lehman MN. The kisspeptin/ neurokinin B/dynorphin (KNDy) cell population of the arcuate nucleus: sex differences and effects of prenatal testosterone in sheep. Endocrinology 2010; 151:301-311.
46. Cheon KW, Lee HS, Parhar IS, Kang IS. Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle. Mol Hum Reprod 2001;7:447-452.
47. Cheung LW,Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 2008;275:5479-5495.
48. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006; 66:10902-10910.
49. Chi L, Zhou W, Prikhozhan A, Flanagan C, Davidson JS, Golembo M, Illing N, Millar RP, Sealfon SC. Cloning and characterization of the human GnRH receptor. Mol Cell Endocrinol 1993;91:R1-R6.
50. Choi JH, Gilks CB, Auersperg N, Leung PC. Immunolocalization of gonadotropinreleasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 2006;91:4562-4570.
51. Chou CS, MacCalman CD, Leung PC. Differential effects of gonadotropin-releasing hormone I and II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human decidual stromal cells in vitro. J Clin Endocrinol Metab 2003;88:3806-3815.
52. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004;115(Suppl 1):S44-S56.
53. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405.
54. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5:162-168.
55. Crowley WF, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH). J Clin Endocrinol Metab 1980;51:173-175.
56. Currie AJ, Fraser HM, Sharpe RM. Human placental receptors for luteinizing hormone releasing hormone. Biochem Biophys Res Commun 1981;99:332-338.
57. da Silva JL, Paulino E, Dias MF, de Melo AC. Endometrial cancer: redefining the molecular-targeted approach. Cancer Chemother Pharmacol 2015;1:1-11.
58. Dahl SK, Amstalden M, Coolen L, Fitzgerald M, Lehman M. Dynorphin immunoreactive fibers contact GnRH neurons in the human hypothalamus. Reprod Sci 2009; 16:781-787.
59. De Vos M, Smitz J,Woodruff TK. Fertility preservation in women with cancer. Lancet 2014;384:1302-1310.
60. DePaolo LV, King RA, Carrillo AJ. In vivo and in vitro examination of an autoregulatory mechanism for luteinizing hormone-releasing hormone. Endocrinology 1987; 120:272-279.
61. Deragon KL, Sower SA. Effects of lamprey gonadotropin-releasing hormone-III on steroidogenesis and spermiation in male sea lampreys. Gen Comp Endocrinol 1994; 95:363-367.
62. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O et al. Epithelial ovarian cancer: an overview. World J Transl Med 2014;3:1-8.
63. Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014;21:363-371.
64. DiVall SA, Herrera D, Sklar B, Wu S, Wondisford F, Radovick S, Wolfe A. Insulin receptor signaling in the GnRH neuron plays a role in the abnormal GnRH pulsatility of obese female mice. PLoS One 2015;10:e0119995.
65. Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet 2009;17:139-146.
66. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091-4095.
67. Dwyer AA, Hayes FJ, Plummer L, Pitteloud N, Crowley WF Jr. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. J Clin EndocrinolMetab 2010;95:4235-4243.
68. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
69. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics 1996;97:517-519.
70. Eftekhar M, Pourmasumi S, Karimi-Zarchi M. Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies. Iran J Reprod Med 2014;12:377-382.
71. Eicke N, Gunthert AR, Emons G, Grundker C. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol 2006;29:1223-1229.
72. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-5446.
73. Emons G, Kaufmann M, Gorchev G, Tsekova V, Grundker C, Gunthert AR, Hanker LC, Velikova M, Sindermann H, Engel J et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-461.
74. Emons G, Gorchev G, Harter P, Wimberger P, Stahle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Grundker C et al. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int J Gynecol Cancer 2014;24:260-265.
75. Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007; 3:157-167.
76. Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 2005; 83(Suppl 1):1125-1133.
77. Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007;4:652-658.
78. Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet 2012; 286:437-442.
79. Eppig JJ. Oocyte control of ovarian follicular development and function in mammals. Reproduction 2001;122:829-838.
80. Eskenazi B,Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-258.
81. Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl) 2015;11:19-28.
82. Fan NC, Jeung EB, Peng C, Olofsson JI, Krisinger J, Leung PC. The human gonadotropin-releasing hormone (GnRH) receptor gene: cloning, genomic organization and chromosomal assignment. Mol Cell Endocrinol 1994;103:R1-R6.
83. Filicori M, Michelacci L, Ferrari P, Campaniello E, Pareschi A, Flamigni C. Triplet pregnancy after low-dose pulsatile gonadotropin-releasing hormone in polycystic ovarian disease. Am J Obstet Gynecol 1986;155:768-769.
84. Filicori M, Flamigni C, Meriggiola MC, Cognigni G, Valdiserri A, Ferrari P, Campaniello E. Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives. Fertil Steril 1991;56:1-13.
85. Finas D, Hornung D, Diedrich K, Schultze-Mosgau A. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother 2006;7:2155-2168.
86. Fister S, Gunthert AR, Aicher B, Paulini KW, Emons G, Grundker C. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 2009;69:6473-6481.
87. Forni PE, Wray S. GnRH, anosmia and hypogonadotropic hypogonadism-where are we? Front Neuroendocrinol 2015;36:165-177.
88. Fortin J, Lamba P, Wang Y, Bernard DJ. Conservation of mechanisms mediating gonadotrophin-releasing hormone 1 stimulation of human luteinizing hormone beta subunit transcription. Mol Hum Reprod 2009;15:77-87.
89. Franco JG Jr, Oliveira JB, Petersen CG, Mauri AL, Baruffi R, Cavagna M. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility. Med Hypotheses 2012;78:442-445.
90. Friedman AJ, Hornstein MD. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain. Fertil Steril 1993;60:236-241.
91. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198-2207.
92. Grumbach M, Kaplan S. The neuroendocrinology of human puberty: an ontogenetic perspective. In Grumbach MM, Sizonenko PC, Aubert M (eds). Control of the Onset of Puberty. Baltimore, MD: Williams & Wilkins, 1990, 1-62.
93. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003;1:65.
94. Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropinreleasing hormone system in gynecological cancers. Eur J Endocrinol 2002a; 146:1-14.
95. Grundker C, Volker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002b;187:528-537.
96. Grundker C, Gunthert AR, Hellriegel M, Emons G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004;151:619-628.
97. Guerriero KA, Keen KL, Terasawa E. Developmental increase in kisspeptin-54 release in vivo is independent of the pubertal increase in estradiol in female rhesus monkeys (Macaca mulatta). Endocrinology 2012;153:1887-1897.
98. Gunthert AR, Grundker C, Hollmann K, Emons G. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 2002;294:11-15.
99. Gunthert AR, Grundker C, Olota A, Lasche J, Eicke N, Emons G. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 2005;153:613-625.
100. Hall JE. Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 2007;25:344-351.
101. Hall JE, Lavoie HB, Marsh EE, Martin KA. Decrease in gonadotropin-releasing hormone (GnRH) pulse frequency with aging in postmenopausal women. J Clin Endocrinol Metab 2000;85:1794-1800.
102. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf) 2010;72:731-737.
103. Hanchate NK, Giacobini P, Lhuillier P, Parkash J, Espy C, Fouveaut C, Leroy C, Baron S, Campagne C, Vanacker C et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet 2012;8:e1002896.
104. Harrison GS,Wierman ME, NettTM,Glode LM.Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004;11:725-748.
105. Hayes FJ, Crowley WF. Gonadotropin pulsations across development. Horm Res 1998; 49:163-168.
106. Hayflick JS, Adelman JP, Seeburg PH. The complete nucleotide sequence of the human gonadotropin-releasing hormone gene. Nucleic Acids Res 1989;17:6403-6404.
107. Herbison AE, Pape JR.Newevidence for estrogen receptors in gonadotropin-releasing hormone neurons. Front Neuroendocrinol 2001;22:292-308.
108. Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003; 3:660-666.
109. Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG. Immune interactions in endometriosis. Expert Rev Clin Immunol 2011;7:611-626.
110. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014;348:g1752.
111. Hislop JN, Madziva MT, Everest HM, Harding T, Uney JB, Willars GB, Millar RP, Troskie BE, Davidson JS, McArdle CA. Desensitization and internalization of human and xenopus gonadotropin-releasing hormone receptors expressed in alphaT4 pituitary cells using recombinant adenovirus. Endocrinology 2000;141:4564-4575.
112. Hong IS, Cheung AP, Leung PC. Gonadotropin-releasing hormones I and II induce apoptosis in human granulosa cells. J Clin Endocrinol Metab 2008;93:3179-3185.
113. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or -II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrinol Metab 2012;97:525-534.
114. Hrabovszky E. Neuroanatomy of the human hypothalamic kisspeptin system. Neuroendocrinology 2014;99:33-48.
115. Hrabovszky E, Liposits Z. Afferent neuronal control of type-I gonadotropin releasing hormone neurons in the human. Front Endocrinol (Lausanne) 2013;4:130.
116. Hrabovszky E, Ciofi P, Vida B, Horvath MC, Keller E, Caraty A, Bloom SR, Ghatei MA, Dhillo WS,Liposits Z et al. The kisspeptin system of the human hypothalamus: sexual dimorphism and relationship with gonadotropin-releasing hormone and neurokinin B neurons. Eur J Neurosci 2010;31:1984-1998.
117. Hrabovszky E, Sipos MT, Molnár CS, Ciofi P, Borsay B, Gergely P, Herczeg L, Bloom SR, Ghatei MA,Dhillo WSet al. Lowdegree of overlap between kisspeptin, neurokinin B, and dynorphin immunoreactivities in the infundibular nucleus of young male human subjects challenges the KNDy neuron concept. Endocrinology 2012; 153:4978-4989.
118. Hu L, Gustofson RL, Feng H, Leung PK, Mores N, Krsmanovic LZ, Catt KJ. Converse regulatory functions of estrogen receptor-alpha and -beta subtypes expressed in hypothalamic gonadotropin-releasing hormone neurons. Mol Endocrinol 2008; 22:2250-2259.
119. Hu Y, Yu H, Shaw G, Pask AJ, Renfree MB. Kallmann syndrome 1 gene is expressed in the marsupial gonad. Biol Reprod 2011;84:595-603.
120. Huang F,Wang H,Zou Y, Liu Q, Cao J, Yin T. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int J Clin Exp Pathol 2013;6:2487-2496.
121. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358:1793-1803.
122. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20:1213-1220.
123. Ibáñez L, Díaz R, López-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009;10:63-76.
124. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropinreleasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994;55:144-148.
125. Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T. Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 1996;77:132-137.
126. Imai A, Furui T, Tamaya T, Mills GB. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J Clin Endocrinol Metab 2000;85:3370-3375.
127. Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995;55:817-822.
128. Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online 2009;19:472-477.
129. Iwashita M, Evans MI, Catt KJ. Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 1986; 62:127-133.
130. Janaky T, Juhasz A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Milovanovic S, Redding TW, Rekasi Z, Nagy A et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 1992;89:972-976.
131. Jayasena CN, Comninos AN, De Silva A, Abbara A, Veldhuis JD, Nijher GM, Ganiyu-Dada Z, Vaal M, Stamp G, Ghatei MA et al. Effects of neurokinin B administration on reproductive hormone secretion in healthy men and women. J Clin Endocrinol Metab 2014;99:E19-E27.
132. Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 2015;15:396.
133. Kaiser UB, Conn PM, Chin WW. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 1997; 18:46-70.
134. Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of humanGnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 1994;106:145-149.
135. Kakar SS, Malik MT, Winters SJ, Mazhawidza W. Gonadotropin-releasing hormone receptors: structure, expression, and signaling transduction. Vitam Horm 2004; 69:151-207.
136. Kalra SP. Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr Rev 1993;14:507-538.
137. Kang SK, Tai CJ, Cheng KW, Leung PC. Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells. Mol Cell Endocrinol 2000;170:143-151.
138. Karsch FJ. Central actions of ovarian steroids in the feedback regulation of pulsatile secretion of luteinizing hormone. Annu Rev Physiol 1987;49:365-382.
139. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structurefunction studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986;7:44-66.
140. Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L,Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr 2010; 157:894-899.
141. Keller PJ, Gerber C. Effect of sublingual, intravenous and intramuscular administration of synthetic LH-releasing hormone in the human. Horm Metab Res 1973;5:64-65.
142. Kerdelhué B, Lenoir V, Scholler R, Jones HW. Substance P plasma concentration during the LH preovulatory surge of the menstrual cycle in the human. Neuro Endocrinol Lett 2006;27:359-364.
143. Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, Masuzaki H. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod 2010;25:2878-2890.
144. Kim K, Patel L, Tobet S, King J, Rubin B, Stopa E. Gonadotropin-releasing hormone immunoreactivity in the adult and fetal human olfactory system. Brain Res 1999; 826:220-229.
145. Kim KY, Choi KC, Park SH, Chou CS, Auersperg N, Leung PC. Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2004;89:3020-3026.
146. Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol 1994;170:96-102.
147. Kousta E, White DM, Piazzi A, Loumaye E, Franks S. Successful induction ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Hum Reprod 1996; 11:70-71.
148. Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, Flerko B. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol 2002;14:647-655.
149. Kraus S, Naor Z, Seger R. Intracellular signaling pathwaysmediated by the gonadotropinreleasing hormone (GnRH) receptor. Arch Med Res 2001;32:499-509.
150. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5: 12-16.
151. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update 2011;17:734-740.
152. Labrie F. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. Endocr Relat Cancer 2014;21:R301-R317.
153. Landy H, Schneyer AL, Whitcomb RW, Crowley WF. Validation of highly specific and sensitive radioimmunoassays for lutropin, follitropin, and free alpha subunit in unextracted urine. Clin Chem 1990;36:340-344.
154. Latimer VS, Rodrigues SM, Garyfallou VT, Kohama SG, White RB, Fernald RD, Urbanski HF. Two molecular forms of gonadotropin-releasing hormone (GnRH-I and GnRH-II) are expressed by two separate populations of cells in the rhesus macaque hypothalamus. Brain Res Mol Brain Res 2000;75:287-292.
155. Lebovic DI, Mueller MD,Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001; 75:1-10.
156. Lehman MN, Robinson JE, Karsch FJ, Silverman AJ. Immunocytochemical localization of luteinizing hormone-releasing hormone (LHRH) pathways in the sheep brain during anestrus and the mid-luteal phase of the estrous cycle. J Comp Neurol 1986; 244:19-35.
157. Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/ dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology 2010;151:3479-3489.
158. Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 2003;202:145-153.
159. Leyendecker G, Struve T, Plotz EJ. Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol 1980;229:177-190.
160. Li P, LiY, Yang CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis. Medicine (Baltimore) 2014;93:e260.
161. Lim S, Pnueli L, Tan JH, Naor Z, Rajagopal G, Melamed P. Negative feedback governs gonadotrope frequency-decoding of gonadotropin releasing hormone pulsefrequency. PLoS One 2009;4:e7244.
162. Limonta P, Manea M. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: current options and emerging strategies. Cancer Treat Rev 2013;39:647-663.
163. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing-hormone-releasing hormone agonists on the human prostatic-cancer cell-line lncap. J Clin Endocrinol Metab 1992;75:207-212.
164. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999;140:5250-5256.
165. Limonta P, Marelli MM, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 2012;33:784-811.
166. Lin LS, Roberts VJ, Yen SS. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 1995;80:580-585.
167. Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: the global framework. Cancer Treat Rev 2014;40:1019-1027.
168. Liu J, Patel B. Central causes of amenorrhea 2013. South Dartmouth (MA).
169. Liu JH, Yen SS. The use of gonadotropin-releasing hormone for the induction of ovulation. Clin Obstet Gynecol 1984;27:975-982.
170. Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM,Webster NJ. Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptormediated signaling in L beta T2 cells. J Biol Chem 2002;277:32099-32108.
171. Loumaye E, Catt KJ. Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells. Science 1982;215:983-985.
172. Luxardi G, Galli A, Forlani S, Lawson K, Maina F, Dono R. Glypicans are differentially expressed during patterning and neurogenesis of early mouse brain. Biochem Biophys Res Commun 2007;352:55-60.
173. Mahajan N. Fertility preservation in female cancer patients: an overview. J Hum Reprod Sci 2015;8:3-13.
174. Marshall JC, Dalkin AC, Haisenleder DJ, Paul SJ, Ortolano GA, Kelch RP. Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog Horm Res 1991;47:155-187; discussion 188-159.
175. Martin JB. Molecular genetics in neurology. Ann Neurol 1993;34:757-773.
176. Martins WP, Ferriani RA, Navarro PA, Nastri CO.GnRHagonist during luteal phase for women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2015; doi:10.1002/uog.1487.
177. McArdle CA. Gonadotropin-releasing hormone receptor signaling: biased and unbiased. Mini Rev Med Chem 2012;12:841-850.
178. McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 2002;173:1-11.
179. McCartney CR, Blank SK, Marshall JC. Progesterone acutely increases LH pulse amplitude but does not acutely influence nocturnal LH pulse frequency slowing during the late follicular phase in women. Am J Physiol Endocrinol Metab 2007; 292:E900-E906.
180. McGillivray SM, Thackray VG, Coss D, Mellon PL. Activin and glucocorticoids synergistically activate follicle-stimulating hormone beta-subunit gene expression in the immortalized LbetaT2 gonadotrope cell line. Endocrinology 2007;148:762-773.
181. Meczekalski B, Podfigurna-Stopa A, Smolarczyk R, Katulski K, Genazzani AR. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecol Endocrinol 2013;29:296-300.
182. Melamed A, Katz Eriksen JL, Hinchcliff EM,Worley MJ Jr, Berkowitz RS, Horowitz NS, Muto MG, Urman RD, Feltmate CM. Same-day discharge after laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol 2015;doi:10.1245/s10434-015-4582-4.
183. Merchenthaler I, Görcs T, Sétáló G, Petrusz P, Flerkó B. Gonadotropin-releasing hormone (GnRH) neurons and pathways in the rat brain. Cell Tissue Res 1984; 237:15-29.
184. Meresman GF, Bilotas M, Abello V, Buquet R,Tesone M, Sueldo C. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005;84:459-463.
185. Millar RP. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003; 14:35-43.
186. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005;88:5-28.
187. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol 2013;9:451-466.
188. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 2001;98:9636-9641.
189. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropinreleasing hormone receptors. Endocr Rev 2004;25:235-275.
190. Millar RP, Pawson AJ, Morgan K, Rissman EF, Lu ZL. Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol 2008;29:17-35.
191. Mitchell AL, Dwyer A, Pitteloud N, Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol Metab 2011;22:249-258.
192. Mittelman-Smith MA, Wong AM, Kathiresan AS, Micevych PE. Classical and membrane-initiated estrogen signaling in an in vitro model of anterior hypothalamic kisspeptin neurons. Endocrinology 2015;156:2162-2173.
193. Moenter SM, Caraty A, Locatelli A, Karsch FJ. Pattern of gonadotropin-releasing hormone (GnRH) secretion leading up to ovulation in the ewe: existence of a preovulatory GnRH surge. Endocrinology 1991;129:1175-1182.
194. Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M, Limonta P. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 2006;6:257-269.
195. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab 2009;94:1761-1767.
196. Montagnani Marelli M, Manea M, Moretti RM, Marzagalli M, Limonta P. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. Int J Oncol 2015;46:243-253.
197. Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, Kennedy SH, Zondervan KT. The search for genes contributing to endometriosis risk. Hum Reprod Update 2008;14:447-457.
198. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-932.
199. Morimoto C, Osuga Y, Yano T, Takemura Y, Harada M, Hirata T, Hirota Y, Yoshino O, Koga K, Kugu K et al. GnRH II as a possible cytostatic regulator in the development of endometriosis. Hum Reprod 2005;20:3212-3218.
200. Mukherjee T, Barad D, Turk R, Freeman R.Arandomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am J Obstet Gynecol 1996;175:105-109.
201. Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005; 73:851-859.
202. Nagy A, SchallyAV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-7273.
203. Naor Z. Is arachidonic acid a second messenger in signal transduction? Mol Cell Endocrinol 1991;80:C181-C186.
204. Naor Z. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol 2009;30:10-29.
205. Navarro VM.Newinsights into the control of pulsatileGnRHrelease: the role of Kiss1/ neurokinin B neurons. Front Endocrinol (Lausanne) 2012;3:48.
206. Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002; 143:737-743.
207. Neill JD, Musgrove LC, Duck LW. Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab 2004;15:383-392.
208. Nirgianakis K, Bersinger NA, McKinnon B, Kostov P, Imboden S, Mueller MD. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol 2013;170:550-554.
209. Nnoaham KE, Hummelshoj L,Webster P, d'Hooghe T, de Cicco Nardone F, de Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril 2011;96:366-373 e368.
210. Oliveira JB, Baruffi R, Petersen CG, Mauri AL, Cavagna M, Franco JG Jr. Administration of single-doseGnRHagonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol 2010;8:107.
211. Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E.GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked? Clin Exp Obstet Gynecol 2006;33:197-199.
212. Orvieto R,HodE, Volodarsky M, Homburg R, Rabinson J, Meltcer S. Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones? Fertil Steril 2008;89:1269-1272.
213. Orvieto R, Brengauz M, Feldman B. A novel approach to normal responder patient with repeated implantation failures-a case report. Gynecol Endocrinol 2015;31:435-437.
214. Padula AM. GnRH analogues-agonists and antagonists. Anim Reprod Sci 2005; 88:115-126.
215. Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Zupi E, Lombardi G, Nappi C, Panici PL, Zullo F. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002;87:3603-3608.
216. Pelletier JC, Chengalvala M, Cottom J, Feingold I, Garrick L, Green D, Hauze D, Huselton C, Jetter J, Kao W et al. 2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem 2008;16:6617-6640.
217. Piet R, de Croft S, Liu X, Herbison AE. Electrical properties of kisspeptin neurons and their regulation of GnRH neurons. Front Neuroendocrinol 2015;36:15-27.
218. Pietranera L, Brocca ME, Roig P, Lima A, Garcia-Segura LM, De Nicola AF. Estrogens are neuroprotective factors for hypertensive encephalopathy. J Steroid Biochem Mol Biol 2015;146:15-25.
219. Plant TM. Neuroendocrine control of the onset of puberty. Front Neuroendocrinol 2015; 38:73-88.
220. Plant TM, Ramaswamy S, Simorangkir D, Marshall GR. Postnatal and pubertal development of the rhesus monkey (Macaca mulatta) testis. Ann N Y Acad Sci 2005;1061:149-162.
221. Platteeuw L, D'Hooghe T. Novel agents for the medical treatment of endometriosis. Curr Opin Obstet Gynecol 2014;26:243-252.
222. Pohl CR, deRidder CM, Plant TM. Gonadal and nongonadal mechanisms contribute to the prepubertal hiatus in gonadotropin secretion in the female rhesus monkey (Macaca mulatta). J Clin Endocrinol Metab 1995;80:2094-2101.
223. Prague JK, Dhillo WS. Potential clinical use of kisspeptin. Neuroendocrinology 2015; 3:238-245.
224. Prentice A. Regular review: endometriosis. BMJ 2001;323:93-95.
225. Quinton R, Hasan W, Grant W, Thrasivoulou C, Quiney RE, Besser GM, Bouloux PM. Gonadotropin-releasing hormone immunoreactivity in the nasal epithelia of adults with Kallmann's syndrome and isolated hypogonadotropic hypogonadism and in the early midtrimester human fetus. J Clin Endocrinol Metab 1997;82:309-314.
226. Raga F, Casan EM, Kruessel JS,Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998;59:661-669.
227. Rahmioglu N, Nyholt DR, Morris AP, Missmer SA, Montgomery GW, Zondervan KT. Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. Hum Reprod Update 2014;20:702-716.
228. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, Lee H, Boepple P et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357:863-873.
229. Rama S, Rao AJ. Embryo implantation and GnRH antagonists: the search for the human placental GnRH receptor. Hum Reprod 2001;16:201-205.
230. Ramaswamy S, Seminara SB, Ali B, Ciofi P, Amin NA, Plant TM. Neurokinin B stimulates GnRH release in the male monkey (Macaca mulatta) and is colocalized with kisspeptin in the arcuate nucleus. Endocrinology 2010;151:4494-4503.
231. Ramaswamy S, Seminara SB, Plant TM. Evidence from the agonadal juvenile male rhesus monkey (Macaca mulatta) for the view that the action of neurokinin B to trigger gonadotropin-releasing hormone release is upstream from the kisspeptin receptor. Neuroendocrinology 2011;94:237-245.
232. Rance NE. Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. Peptides 2009;30:111-122.
233. Rapisarda JJ, Bergman KS, Steiner RA, Foster DL. Response to estradiol inhibition of tonic luteinizing hormone secretion decreases during the final stage of puberty in the rhesus monkey. Endocrinology 1983;112:1172-1179.
234. Reid RL, Leopold GR, Yen SS. Induction of ovulation and pregnancy with pulsatile luteinizing hormone releasing factor: dosage and mode of delivery. Fertil Steril 1981;36:553-559.
235. Roland AV, Moenter SM. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models. Front Neuroendocrinol 2014;35:494-511.
236. Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle 2013;12:3245-3246.
237. Schally AV. LH-RH analogues: I. Their impact on reproductive medicine. Gynecol Endocrinol 1999;13:401-409.
238. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14.
239. Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971;43:393-399.
240. Schally AV, Engel JB, Emons G, Block NL, Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 2011;8:11-25.
241. Scheiber M, Liu J. The Use of Gonadotropin-Releasing Hormone to Induce Ovulation. Glob. libr. women's med. 2011.
242. Sealfon SC,Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205.
243. Seeburg PH, Mason AJ, Stewart TA, Nikolics K. The mammalian GnRH gene and its pivotal role in reproduction. Recent Prog Horm Res 1987;43:69-98.
244. Semple RK, Achermann JC, Ellery J, Farooqi IS, Karet FE, Stanhope RG, O'rahilly S, Aparicio SA. Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90:1849-1855.
245. Shibata S, Sato H, Ota H, Karube A, Takahashi O, Tanaka T. Involvement of annexin Vin antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol Oncol 1997;66:217-221.
246. Shinkawa O, Furuhashi N, Fukaya T, Suzuki M, Kono H, Tachibana Y. Changes of serum gonadotropin levels and sex differences in premature and mature infant during neonatal life. J Clin Endocrinol Metab 1983;56:1327-1331.
247. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
248. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
249. Simavli S, Thompson IR, Maguire CA, Gill JC, Carroll RS, Wolfe A, Kaiser UB, Navarro VM. Substance p regulates puberty onset and fertility in the female mouse. Endocrinology 2015;156:2313-2322.
250. Sisk CL, Foster DL. The neural basis of puberty and adolescence. Nat Neurosci 2004; 7:1040-1047.
251. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014;20:485-500.
252. Skrapits K, Borsay B, Herczeg L, Ciofi P, Liposits Z, Hrabovszky E. Neuropeptide co-expression in hypothalamic kisspeptin neurons of laboratory animals and the human. Front Neurosci 2015;9:29.
253. Smith JT, Cunningham MJ, Rissman EF, Clifton DK, Steiner RA. Regulation of Kiss1 gene expression in the brain of the female mouse. Endocrinology 2005;146: 3686-3692.
254. Smith JT, Shahab M, Pereira A, Pau KY, Clarke IJ. Hypothalamic expression of KISS1 and gonadotropin inhibitory hormone genes during the menstrual cycle of a non-human primate. Biol Reprod 2010;83:568-577.
255. So WK, Cheng JC, Poon SL, Leung PC. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 2008;275:5496-5511.
256. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 1984;58:378-383.
257. Sower SA, Chiang YC, Lovas S, Conlon JM. Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinology 1993; 132:1125-1131.
258. Stephens SB, Tolson KP, Rouse ML, Poling MC, Hashimoto-Partyka MK, Mellon PL, Kauffman AS. Absent progesterone signaling in kisspeptin neurons disrupts the LH surge and impairs fertility in female mice. Endocrinology 2015;156:3091-3097.
259. Stern CJ, Gook D, Hale LG, Agresta F, Oldham J, Rozen G, Jobling T. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod 2013; 28:2996-2999.
260. Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994;15:462-499.
261. Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back ConsensusWorking Group. Fertil Steril 1999;71:420-424.
262. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99: 709-719.
263. Sykiotis GP, Pitteloud N, Seminara SB, Kaiser UB, Crowley WF. Deciphering genetic disease in the genomic era: the model of GnRH deficiency. Sci Transl Med 2010; 2:32rv32.
264. Tammela TL. Endocrine prevention and treatment of prostate cancer. Mol Cell Endocrinol 2012;360:59-67.
265. Tan O, Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropinreleasing hormone antagonists. Curr Opin Obstet Gynecol 2011;23:238-244.
266. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002; 55:123-130.
267. Terasawa E, Guerriero KA, Plant TM. Kisspeptin and puberty in mammals. Adv Exp Med Biol 2013;784:253-273.
268. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006; 21:2572-2579.
269. Thornton P, Silverman LA, Geffner ME, Neely EK, Gould E, Danoff TM. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev 2014;11:306-317.
270. Tomasi-Cont N, Lambertini M, Hulsbosch S, Peccatori AF, Amant F. Strategies for fertility preservation in young early breast cancer patients. Breast 2014; 23:503-510.
271. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, Serin A, Mungan NO, Cook JR, Ozbek MN et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009;41:354-358.
272. Tsutsui K, Saigoh E, Ukena K,Teranishi H, Fujisawa Y, Kikuchi M, Ishii S, Sharp PJ.Anovel avian hypothalamic peptide inhibiting gonadotropin release. Biochem Biophys Res Commun 2000;275:661-667.
273. Tsutsumi R, Webster NJ. GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J 2009;56:729-737.
274. Tsutsumi R, Mistry D, Webster NJ. Signaling responses to pulsatile gonadotropinreleasing hormone in LbetaT2 gonadotrope cells. J Biol Chem 2010;285: 20262-20272.
275. Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropinreleasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013;24:2224-2235.
276. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015; 7:CD009154.
277. Velasco I, Rueda J, Acien P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod 2006;12:377-381.
278. Veldhuis JD, Keenan DM, Liu PY, Iranmanesh A, Takahashi PY, Nehra AX. The aging male hypothalamic-pituitary-gonadal axis: pulsatility and feedback. Mol Cell Endocrinol 2009;299:14-22.
279. Verma S, Kirigiti MA, Millar RP, Grove KL, Smith MS. Endogenous kisspeptin tone is a critical excitatory component of spontaneous GnRH activity and the GnRH response to NPY and CART. Neuroendocrinology 2014;99:190-203.
280. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD, Emons G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2003;90:552-559.
281. Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril 2014;102:808-815 e801.
282. Waimey KE, Duncan FE, Su HI, Smith K,Wallach H, Jona K, Coutifaris C, Gracia CR, Shea LD, Brannigan RE et al. Future directions in oncofertility and fertility preservation: a report from the 2011 Oncofertility Consortium Conference. J Adolesc Young Adult Oncol 2013;2:25-30.
283. Walters K, Wegorzewska IN, Chin YP, Parikh MG, Wu TJ. Luteinizing hormonereleasing hormone I (LHRH-I) and its metabolite in peripheral tissues. Exp Biol Med (Maywood) 2008;233:123-130.
284. Watanabe Y, Uenoyama Y, Suzuki J, Takase K, Suetomi Y, Ohkura S, Inoue N, Maeda KI, Tsukamura H. Oestrogen-induced activation of preoptic kisspeptin neurones may be involved in the luteinising hormone surge in male and female Japanese monkeys. J Neuroendocrinol 2014;26:909-917.
285. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000;17:1063-1069.
286. Wetsel WC, Valença MM, Merchenthaler I, Liposits Z, López FJ,Weiner RI, Mellon PL, Negro-Vilar A. Intrinsic pulsatile secretory activity of immortalized luteinizing hormone-releasing hormone-secreting neurons. Proc Natl Acad Sci USA 1992; 89:4149-4153.
287. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-309.
288. White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K. Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology 2008; 88:67-79.
289. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 2015;125:89-98.
290. Witchel S, Plant T. Puberty: gonadarche and adrenarche. In Strauss JF, Barbieri RL (eds). Yen and Jaffe's Reproductive Endocrinology. Philadelphia, PA: Saunders Elsevier, 2014, 382-421.
291. Wray S, Hoffman G. A developmental study of the quantitative distribution of LHRH neurons within the central nervous system of postnatal male and female rats. J Comp Neurol 1986;252:522-531.
292. Wu HM,Wang HS, Huang HY, Soong YK, MacCalman CD, Leung PC. GnRH signaling in intrauterine tissues. Reproduction 2009;137:769-777.
293. Wu HM, Huang HY, Lee CL, Soong YK, Leung PC,Wang HS. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy. Biol Reprod 2015;92:1-11.
294. Yan X, Yuan C, Zhao N, Cui Y, Liu J. Prenatal androgen excess enhances stimulation of the GNRH pulse in pubertal female rats. J Endocrinol 2014;222:73-85.
295. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 1994;91:7090-7094.
296. Yoshida H, Yabuno A, Fujiwara K. Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Des Devel Ther 2015;9:2351-2358.
297. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014;10:CD008046.
298. Yu B, Ruman J, Christman G. The role of peripheral gonadotropin-releasing hormone receptors in female reproduction. Fertil Steril 2011;95:465-473.
299. Zito G, Luppi S, Giolo E, Martinelli M, Venturin I, Di Lorenzo G, Ricci G. Medical treatments for endometriosis-associated pelvic pain. Biomed Res Int 2014; 2014:191967.